JP2023551734A5 - - Google Patents

Info

Publication number
JP2023551734A5
JP2023551734A5 JP2023533830A JP2023533830A JP2023551734A5 JP 2023551734 A5 JP2023551734 A5 JP 2023551734A5 JP 2023533830 A JP2023533830 A JP 2023533830A JP 2023533830 A JP2023533830 A JP 2023533830A JP 2023551734 A5 JP2023551734 A5 JP 2023551734A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
antibody
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061755 external-priority patent/WO2022120137A1/en
Publication of JP2023551734A publication Critical patent/JP2023551734A/ja
Publication of JP2023551734A5 publication Critical patent/JP2023551734A5/ja
Pending legal-status Critical Current

Links

JP2023533830A 2020-12-04 2021-12-03 眼の疾患を治療するための組成物及び方法 Pending JP2023551734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
US63/121,629 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (2)

Publication Number Publication Date
JP2023551734A JP2023551734A (ja) 2023-12-12
JP2023551734A5 true JP2023551734A5 (https=) 2024-12-10

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533830A Pending JP2023551734A (ja) 2020-12-04 2021-12-03 眼の疾患を治療するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240059765A1 (https=)
EP (1) EP4255485A4 (https=)
JP (1) JP2023551734A (https=)
KR (1) KR20230117192A (https=)
CN (1) CN116782940A (https=)
AU (1) AU2021391800A1 (https=)
CA (1) CA3200976A1 (https=)
CL (1) CL2023001596A1 (https=)
IL (1) IL303289A (https=)
MX (1) MX2023006591A (https=)
WO (1) WO2022120137A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
EP3380518B1 (en) 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
AU2023262202A1 (en) * 2022-04-29 2024-10-24 Annexon, Inc. Compositions and methods for treating ocular diseases.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Similar Documents

Publication Publication Date Title
JP2023551734A5 (https=)
JP2023517236A5 (https=)
JP2023029557A (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
JP2024150751A5 (https=)
JP2017534646A5 (https=)
JP2021535758A5 (https=)
JP2018527887A5 (https=)
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
JP2017537896A5 (https=)
JP2023542289A5 (https=)
JP2025501028A5 (https=)
JP2022524588A5 (https=)
JP2023542290A5 (https=)
JP2021534797A5 (https=)
JP2016538876A5 (https=)
CN107108727A (zh) 对人vegf‑a有异常强的结合亲和力并具有与人vegf‑b的交叉反应性的抗人vegf抗体
JP2024541680A5 (https=)
JP2017534645A5 (https=)
JP2022512647A5 (https=)
JP2021515793A5 (https=)
JP2023548064A5 (https=)
JP2021520195A5 (https=)
JP2025503614A5 (https=)
JP2025503339A5 (https=)
JP2021512613A5 (https=)